🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Thomas B. Karasic

Incyte (United States)

ORCID: 0000-0001-9157-5392
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib”.

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1467
N/A
0.873DataRank · unranked
24 citations

Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood +9 more

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Annals of Oncology(2024)10.1016/j.annonc.2024.12.011
N/A
0.538DataRank · unranked
35 citations

Daniel DiToro, Francesco Facchinetti, E Martin, P. Peng, Islam Baiev +50 more

DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models

Cancers(2022)10.3390/cancers14164017
N/A
0.416DataRank · unranked
15 citations

Emma E. Furth, Yong Fan, Hee Song, Stephen Pickup, Jianbo Cao +13 more

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma

Nature Communications(2024)10.1038/s41467-024-49915-5
N/A
0.396DataRank · unranked
13 citations

Lee McDaniel, Changgee Chang, Qi Long, Shannon M. Pfeiffer, Jaclyn P. Lyman +37 more

A descriptive study on the treatment and outcomes of patients with platinum-sensitive, advanced, BRCA- or PALB2-related pancreatic cancer who have progressed on rucaparib.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4131
N/A
0DataRank · unranked
2 citations

Mark H. O’Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Natallia Izgur +4 more

Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis

Journal of Cancer Research and Clinical Oncology(2023)10.1007/s00432-023-04590-9
N/A
0DataRank · unranked
19 citations

Ronac Mamtani, Phyllis A. Gimotty, Thomas B. Karasic, Yu‐Xiao Yang, Timothy J. Brown

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps265
N/A
0DataRank · unranked
8 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zishuo Ian Hu +6 more

A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps626
N/A
0DataRank · unranked
3 citations

Andy J. Minn, Erica L. Carpenter, Edgar Ben-Josef, Thomas B. Karasic, Timothy J. Brown

P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107

Annals of Oncology(2023)10.1016/j.annonc.2023.04.284
N/A
0DataRank · unranked
2 citations

Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas B. Karasic, Zelan Hu +7 more

Impact of etiology of hepatocellular carcinoma on treatment outcomes in a real-world database.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.508
N/A
0DataRank · unranked
1 citations

Ronac Mamtani, Phyllis A. Gimotty, Thomas B. Karasic, Yu‐Xiao Yang, Timothy J. Brown

Classification and Regression Trees to Predict for Survival for Patients With Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

JCO Clinical Cancer Informatics(2024)10.1200/cci.23.00220
N/A
0DataRank · unranked
3 citations

Phyllis A. Gimotty, Ronac Mamtani, Thomas B. Karasic, Yu‐Xiao Yang, Timothy J. Brown

A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0632
N/A
0DataRank · unranked
19 citations

Max M. Wattenberg, Nevena Damjanov, Elizabeth Prechtel Dunphy, Mona Jacobs-Small, Maryanne J. Lubas +12 more

Advances in Immunooncology and Precision Medicine in Cholangiocarcinoma

Digestive Disease Interventions(2024)10.1055/s-0044-1787013
N/A
0DataRank · unranked
0 citations

Thomas B. Karasic, Timothy J. Brown

Peripheral blood immune correlates associated with TGF-β inhibition (galunisertib) and stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma (HCC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.4575
N/A
0DataRank · unranked
0 citations

Kim Anna Reiss, Michael A. Giannone, Nevena Damjanov, Elizabeth Prechtel Dunphy, Lisa Dicicco +8 more

Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4102
N/A
0DataRank · unranked
2 citations

Wei-Ting Hwang, Thomas B. Karasic, Anne Marie McCarthy, David E. Kaplan, William J. Chapin

Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child‐Pugh B cirrhosis

Cancer Medicine(2022)10.1002/cam4.4906
N/A
0DataRank · unranked
25 citations

Wei‐Ting Hwang, Thomas B. Karasic, Anne Marie McCarthy, David E. Kaplan, William J. Chapin